Staying up-to-date with all of the current information in the breast cancer treatment armamentarium is crucial for patients and their physicians to navigate the complexities of diagnosis, treatment and survivorship, according to Dr. Debu Tripathy. He added that having up-to-date […]
The Power of Knowledge and Staying Informed in Breast Cancer Care Read More »
Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are released into a person’s blood by tumor cells as they die, according to the National Cancer Institute. A blood sample can then be used to
The Role of Circulating Tumor DNA in Breast Cancer Monitoring Read More »
CURE magazine’s outgoing editor-in-chief reflects on 18 years of progress in cancer care, honors his predecessor and prepares to pass the editorial reins. It has been a special honor to serve as editor-in-chief of CURE magazine for the past 18
We Have Come a Long Way Read More »
All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent that was approved by the FDA on Jan. 27, according to Dr. Debu
Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer Read More »
